StockData
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc. (ACRV) stock

ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$1.15−0.25 (-17.86%)

Close on Nov 20, 2026Market cap $49.28MP/E –Yield –

Acrivon Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Acrivon Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$64.14M. For fiscal 2025 it was -$65.33M. The highest annual figure on record is -$14.22M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$65.33M–
FY2024Dec 31, 2024-$68.44M–
FY2023Dec 31, 2023-$43.93M–
FY2022Dec 31, 2022-$32.28M–
FY2021Dec 31, 2021-$14.22M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$14.95M–
Q1 FY2026Mar 31, 2026-$20.55M–
Q4 FY2025Dec 31, 2025-$15.46M–
Q3 FY2025Sep 30, 2025-$13.18M–
Q2 FY2025Jun 30, 2025-$17.10M–
Q1 FY2025Mar 31, 2025-$19.59M–
Q4 FY2024Dec 31, 2024-$18.19M–
Q3 FY2024Sep 30, 2024-$18.31M–
Q2 FY2024Jun 30, 2024-$14.04M–
Q1 FY2024Mar 31, 2024-$17.90M–
Q4 FY2023Dec 31, 2023-$13.52M–
Q3 FY2023Sep 30, 2023-$9.81M–
Q2 FY2023Jun 30, 2023-$9.22M–
Q1 FY2023Mar 31, 2023-$11.38M–
Q4 FY2022Dec 31, 2022-$9.61M–
Q3 FY2022Sep 30, 2022-$6.95M–
Q2 FY2022Jun 30, 2022-$6.90M–
Q1 FY2022Mar 31, 2022-$8.83M–
Q4 FY2021Dec 31, 2021-$3.76M–

More Acrivon Therapeutics figures

See a number that looks wrong?